Actively Recruiting
Comparing Beta-lactam Alone Versus Beta-lactam Plus Levofloxacin for Treating Streptococcal Bacteremia in Adults
Led by Mahidol University · Updated on 2026-08-21
165
Participants Needed
4
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a randomized, double-blind clinical trial to compare the use of beta-lactam antibiotics alone versus beta-lactam combined with levofloxacin for treating adults with Streptococcal bacteremia. This study focuses on adults aged 18 and older who have confirmed blood infections caused by various Streptococcus species. The trial aims to evaluate the effectiveness of adding levofloxacin to standard beta-lactam therapy in reducing unfavorable outcomes and the duration of bacteremia. Participants already receiving intravenous beta-lactam therapy will continue this treatment and be randomly assigned to receive either intravenous levofloxacin at a dose of 750 mg once daily or a placebo of normal saline. The study treatment will last between 3 to 7 days, with dosing adjusted according to kidney function. Both treatments are administered via IV drip over 90 minutes in a blinded manner to maintain study integrity. During the trial, participants will be monitored for a composite endpoint of unfavorable outcomes within 28 days after infection onset. Researchers will also measure how long the bacteremia lasts during this period. Regular assessments will include clinical evaluations and monitoring to ensure safety. The total study duration for each participant is at least 28 days, during which outcomes and any adverse events will be carefully recorded and analyzed.
CONDITIONS
Brief Title
Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia
Research Team
P
Pinyo Rattanaumpawan
W
Wanwisa Chanapai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here